GN
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF · OTC
$0.77 +7.18% (+$0.05)
1M -6.09%
Market Cap 12.9B $
P/E Ratio 7.97x
Div. Yield 5.76%
ROE 14.23%
Bulios Fair Price
$1.04
35.0% upside
Current Price
$0.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GNMLF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
94 /100
Cheap P/E 7.97x
PEG 1.07x
EV/EBITDA 4.85x
Growth
27 /100
Declining EPS growth 5.63%
Book val. growth 2.83%
Rev. growth 1.19%
Profitability
69 /100
Strong Gross margin 63.25%
FCF margin 4.71%
Net margin 9.52%
Quality
64 /100
Average ROIC 11.97%
Asset turnover 0.70x
ROE 14.23%
Debt
66 /100
Moderate Debt/Equity 0.67x
Net debt/EBITDA 1.43x
Current ratio 1.41x
Stability
67 /100
Stable Beta 0.14x
Profitable years 6
Rev. volatility 8.56%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GNMLF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Juan Marco Sparvieri
Employees
1,465
Headquarters
Mexico City
Upcoming events
21 OCT
Earnings
Upcoming earnings report